Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 4/20 | 0.55 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.55 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.55 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.96 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.58 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 4/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL184868 | 0.98 | LOXL2 (1.00) | LOXL2MAPTCYP4A11CYP4F2CA1 | |
| SCHEMBL6677665 | 0.92 | LOXL2 (0.89) | LOXL2MAPTCYP4A11CYP4F2CA1 | |
| Sulfuric Acid SCHEMBL2363547 | 0.91 | LOXL2 (0.86) | LOXL2MAPTCYP4A11CYP4F2CA1 | |
| Hydrochloric Acid SCHEMBL15239626 | 0.90 | LOXL2 (0.77) | LOXL2MAPTCYP4A11CYP4F2TDP1 | |
| Hydrochloric Acid SCHEMBL15239627 | 0.90 | LOXL2 (0.77) | LOXL2MAPTCYP4A11CYP4F2TDP1 | |
| SCHEMBL12636516 | 0.89 | LOXL2 (0.83) | LOXL2MAPTCYP4A11CYP4F2CA1 | |
| SCHEMBL28267713 | 0.89 | LOXL2 (0.83) | LOXL2MAPTCYP4A11CYP4F2CA1 | |
| SCHEMBL7251467 | 0.89 | LOXL2 (0.83) | LOXL2MAPTCYP4A11CYP4F2CA1 | |
| SCHEMBL28117998 | 0.88 | LOXL2 (0.80) | LOXL2MAPTCYP4A11CA1CA2 | |
| Trifluoroacetic Acid SCHEMBL28281967 | 0.86 | LOXL2 (0.77) | LOXL2MAPTCYP4A11CYP4F2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 895 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118791483-A | 1H-pyrazolo [3,4-b ] pyridine derivative and preparation method and application thereof | 郑州大学 | 2024-10-18 | — | — | CN | claimed |
| CN-118480006-A | Novel pyridazinone compound and preparation method and application thereof | 郑州大学 | 2024-08-13 | — | — | CN | claimed |
| CN-114890947-B | Aromatic heterocyclic compound containing quinoline structural unit, and preparation method and application thereof | 郑州大学 | 2024-07-16 | — | — | CN | claimed |
| CN-114075187-B | Carbonyl pyrazole antitumor compound as well as preparation method and application thereof | 山东大学 | 2023-05-12 | — | — | CN | claimed |
| CN-115806503-A | Selective histone deacetylase inhibitor as well as preparation method and application thereof | 中国海洋大学 | 2023-03-17 | — | — | CN | claimed |
| CN-115784986-A | HDAC6 inhibitor and preparation method and application thereof | 中国海洋大学 | 2023-03-14 | — | — | CN | claimed |
| CN-113831338-B | Histone deacetylase inhibitor and preparation method and application thereof | 中国海洋大学 | 2022-12-20 | — | — | CN | claimed |
| CN-114890947-A | Aromatic heterocyclic compound containing quinoline structural unit and preparation method and application thereof | 郑州大学 | 2022-08-12 | — | — | CN | claimed |
| CN-114075187-A | Carbonyl pyrazole anti-tumor compound and preparation method and application thereof | 山东大学 | 2022-02-22 | — | — | CN | claimed |
| CN-113527195-A | 5-aryl nicotinamide LSD1/HDAC double-target inhibitor, preparation method and application thereof | 新乡医学院 | 2021-10-22 | — | — | CN | claimed |
| CN-113444038-A | 2-aryl isonicotinic acid amide LSD1/HDAC double-target inhibitor, and preparation method and application thereof | 新乡医学院 | 2021-09-28 | — | — | CN | claimed |
| CN-103351397-B | A kind of gambogic acid derivant and its production and use | 东华大学 | 2016-06-08 | — | — | CN | claimed |
| CN-103172540-A | Phenylglycine histone deacetylase inhibitor as well as preparation method and applications thereof | WEIFANG BOCHUANG INTERNAT BIOLOG MEDICAL RES INST | 2013-06-26 | — | — | CN | claimed |
| CN-102532245-B | Ursolic acid derivative and preparation method thereof | UNIV PLA 3RD MILITARY MEDICAL | 2013-05-15 | — | — | CN | claimed |
| CN-102532245-A | Ursolic acid derivative and preparation method thereof | UNIV PLA 3RD MILITARY MEDICAL | 2012-07-04 | — | — | CN | claimed |
| US-12583839-B2 | PD-L1 antagonist compound | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2026-03-24 | — | — | US | disclosed |
| US-20260049102-A1 | A PRO-MOIETY FOR FORMING A PRODRUG SELECTIVELY CLEAVED BY PROSTATE-SPECIFIC ANTIGEN (PSA) | UNIV SYDNEY (AU) | 2026-02-19 | — | — | US | disclosed |
| US-4689182-A | Benzoic acid and benzoic acid ester derivatives having anti-inflammatory and analgesic activity | WARNER-LAMBERT COMPANY (US) | 1987-08-25 | — | — | US | disclosed |
| CN-86108626-A | Phenylformic acid and benzoate derivatives with anti-inflammatory and pain palliation efficacy | — | 1987-07-22 | — | — | CN | disclosed |
| EP-0226223-A2 | Benzoic acid and benzoic acid ester derivatives having anti-inflammatory and analgesic activity | WARNER-LAMBERT COMPANY (US) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049102-A1 | A PRO-MOIETY FOR FORMING A PRODRUG SELECTIVELY CLEAVED BY PROSTATE-SPECIFIC ANTIGEN (PSA) | FOLH1, PSAP, KLK3 | CA2 1255/4885HDAC3 2973/4885HDAC6 1800/4885 |
| US-12583839-B2 | PD-L1 antagonist compound | CD274, PDCD1LG2, PDCD1 | CA2 2232/4885HDAC3 383/4885HDAC6 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.